🎉 M&A multiples are live!
Check it out!

Walvax Biotechnology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Walvax Biotechnology and similar public comparables like AstraZeneca India, Prescient Therapeutics, and GSK India.

Walvax Biotechnology Overview

About Walvax Biotechnology

Walvax Biotechnology Co Ltd is engaged in research and development, production and sales of vaccine products.


Founded

2001

HQ

China
Employees

2.4K+

Website

walvax.com

Financials

LTM Revenue $405M

LTM EBITDA $83.1M

EV

$1.9B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Walvax Biotechnology Financials

Walvax Biotechnology has a last 12-month revenue of $405M and a last 12-month EBITDA of $83.1M.

In the most recent fiscal year, Walvax Biotechnology achieved revenue of $389M and an EBITDA of $79.9M.

Walvax Biotechnology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Walvax Biotechnology valuation multiples based on analyst estimates

Walvax Biotechnology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $567M $389M XXX XXX XXX
Gross Profit $617M $484M XXX XXX XXX
Gross Margin 109% 125% XXX XXX XXX
EBITDA $127M $79.9M XXX XXX XXX
EBITDA Margin 22% 21% XXX XXX XXX
Net Profit $100M $57.8M XXX XXX XXX
Net Margin 18% 15% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Walvax Biotechnology Stock Performance

As of April 15, 2025, Walvax Biotechnology's stock price is CNY 11 (or $1).

Walvax Biotechnology has current market cap of CNY 17.3B (or $2.4B), and EV of CNY 14.0B (or $1.9B).

See Walvax Biotechnology trading valuation data

Walvax Biotechnology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.9B $2.4B XXX XXX XXX XXX $0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Walvax Biotechnology Valuation Multiples

As of April 15, 2025, Walvax Biotechnology has market cap of $2.4B and EV of $1.9B.

Walvax Biotechnology's trades at 4.8x LTM EV/Revenue multiple, and 23.2x LTM EBITDA.

Analysts estimate Walvax Biotechnology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Walvax Biotechnology and 10K+ public comps

Walvax Biotechnology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.9B XXX XXX XXX
EV/Revenue 5.0x XXX XXX XXX
EV/EBITDA 24.1x XXX XXX XXX
P/E 121.4x XXX XXX XXX
P/E/Growth 1.3x XXX XXX XXX
EV/FCF 28.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Walvax Biotechnology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Walvax Biotechnology Valuation Multiples

Walvax Biotechnology's NTM/LTM revenue growth is 18%

Walvax Biotechnology's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Walvax Biotechnology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Walvax Biotechnology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Walvax Biotechnology and other 10K+ public comps

Walvax Biotechnology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -31% XXX XXX XXX XXX
EBITDA Margin 21% XXX XXX XXX XXX
EBITDA Growth -37% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 39% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 33% XXX XXX XXX XXX
G&A Expenses to Revenue 7% XXX XXX XXX XXX
R&D Expenses to Revenue 21% XXX XXX XXX XXX
Opex to Revenue 69% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Walvax Biotechnology Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Walvax Biotechnology M&A and Investment Activity

Walvax Biotechnology acquired  XXX companies to date.

Last acquisition by Walvax Biotechnology was  XXXXXXXX, XXXXX XXXXX XXXXXX . Walvax Biotechnology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Walvax Biotechnology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Walvax Biotechnology

When was Walvax Biotechnology founded? Walvax Biotechnology was founded in 2001.
Where is Walvax Biotechnology headquartered? Walvax Biotechnology is headquartered in China.
How many employees does Walvax Biotechnology have? As of today, Walvax Biotechnology has 2.4K+ employees.
Is Walvax Biotechnology publicy listed? Yes, Walvax Biotechnology is a public company listed on SHE.
What is the stock symbol of Walvax Biotechnology? Walvax Biotechnology trades under 300142 ticker.
When did Walvax Biotechnology go public? Walvax Biotechnology went public in 2011.
Who are competitors of Walvax Biotechnology? Similar companies to Walvax Biotechnology include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of Walvax Biotechnology? Walvax Biotechnology's current market cap is $2.4B
What is the current revenue of Walvax Biotechnology? Walvax Biotechnology's last 12-month revenue is $405M.
What is the current EBITDA of Walvax Biotechnology? Walvax Biotechnology's last 12-month EBITDA is $83.1M.
What is the current EV/Revenue multiple of Walvax Biotechnology? Current revenue multiple of Walvax Biotechnology is 4.8x.
What is the current EV/EBITDA multiple of Walvax Biotechnology? Current EBITDA multiple of Walvax Biotechnology is 23.2x.
What is the current revenue growth of Walvax Biotechnology? Walvax Biotechnology revenue growth between 2023 and 2024 was -31%.
Is Walvax Biotechnology profitable? Yes, Walvax Biotechnology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.